A novel inhibitor of amyloid β (Aβ) peptide aggregation: From high throughput screening to efficacy in an animal model of Alzheimer disease

Journal of Biological Chemistry

Volumn 287, Issue 46, 2012, Pages 38992-39000

  McKoy, Angela Fortner ^a   Chen, Jermont ^a   Schupbach, Trudi ^a   Hecht, Michael H ^a  

^a PRINCETON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; GLYCOPROTEINS; NEURODEGENERATIVE DISEASES; OLIGOMERS; PEPTIDES; TOXICITY;

ALZHEIMER DISEASE; CELLULAR DYSFUNCTION; DROSOPHILA MELANOGASTER; HIGH MOLECULAR WEIGHT; HIGH THROUGHPUT SCREENING; HIGH-THROUGHPUT SCREENS; PEPTIDE AGGREGATION; SMALL MOLECULES;

DIAGNOSIS;

AMYLOID BETA PROTEIN[1-42]; D 737; OLIGOMER; PROTEIN INHIBITOR; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOACCUMULATION; CELL PROTECTION; CONTROLLED STUDY; DROSOPHILA MELANOGASTER; DRUG EFFECT; DRUG EFFICACY; DRUG ISOLATION; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; DRUG SCREENING; DRUG STRUCTURE; FEMALE; HIGH THROUGHPUT SCREENING; LIFESPAN; LOCOMOTION; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; RAT;

EID: 84869016210     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.348037     Document Type: Article

References (38)

1. Alexandrescu, A. (2005) Amyloid accomplices and enforcers. Protein Sci. 14, 1-12
2. Clippingdale, A. B., Wade, J. D., and Barrow, C. J. (2001) The amyloid β peptide and its role in Alzheimer disease. J. Pept. Sci. 7, 227-249 (Pubitemid 32586583)
3. Selkoe, D. J., and Podlisny, M. B. (2002) Deciphering the genetic basis of Alzheimer disease. Annu. Rev. Genomics Hum. Genet. 3, 67-99 (Pubitemid 35217431)
4. Selkoe, D. J, and Schenk, D. (2003) Alzheimer disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol. 43, 545-584 (Pubitemid 37372653)
5. Hardy, J. A., and Higgins, G. A. (1992) Alzheimer disease: the amyloid cascade hypothesis. Science 256, 184-185
6. Selkoe, D. (2001) Alzheimer disease: genes, proteins, and therapy. Physiol. Rev. 81, 741-766
7. Citron, M. (2010) Alzheimer disease: strategies for disease modification. Nat. Rev. Drug Discov. 9, 387-398
8. Tiraboschi, P., Hansen, L. A., Thal, L. J., Corey-Bloom, J. (2004) The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology 62, 1984-1989 (Pubitemid 38738208)
9. Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., and Beyreuther, K. (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U.S.A. 82, 4245-4249 (Pubitemid 15053619)
10. Hardy, J., and Allsop, D. (1991) Amyloid deposition as the central event in the etiology of Alzheimer disease. Trends Pharmacol. Sci. 12, 383-388
11. Hardy, J., and Selkoe, D. (2002) The amyloid hypothesis of Alzheimer disease: progress and problems on the road to therapeutics. Science 297, 353-356 (Pubitemid 34790756)
12. Walsh, D. M., and Selkoe, D. J. (2007) Aβ oligomers - a decade of discovery. J. Neurochem. 101, 1172-1184
13. Walsh, D. M., and Selkoe, D. J. (2004) Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept. Lett. 11, 213-228 (Pubitemid 38689025)
14. Glabe, C. (2008) Structural classification of toxic amyloid oligomers. J. Biol. Chem. 283, 29639-29643
15. Shi, C., Zhao, L., Zhu, B., Li, Q., Yew, D. T., Yao, Z., and Xu, J. (2009) Protective effects of Ginkgo biloba extract (EGb761) and its constituents quercetin and ginkgolide B against β-amyloid peptide-induced toxicity in SH-SY5Y cells. Chem. Biol. Interact. 181, 115-123
16. Necula, M., Kayed, R., Milton, S., and Glabe, C. (2007) Small molecule inhibitors of aggregation indicate that amyloid β oligomerization and fibrillization pathways are independent and distinct. J. Biol. Chem. 282, 10311-10324 (Pubitemid 47093410)
17. Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., and Glabe, C. G. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489 (Pubitemid 36444329)
18. Kim, W., Kim, Y., Min, J., Kim, D. J., Chang, Y. T., and Hecht, M. H. (2006) A high throughput screen for compounds that inhibit aggregation of the Alzheimer peptide. ACS Chem. Biol. 1, 461-469
19. Waldo, G. S., Standish, B. M., Berendzen, J., and Terwilliger, T. C. (1999) Rapid protein-folding assay using green fluorescent protein. Nat. Biotechnol. 17, 691-695 (Pubitemid 29316148)
20. Seiler, K. P., George, G. A., Happ, M. P., Bodycombe, N. E., Carrinski, H. A., Norton, S., Brudz, S., Sullivan, J. P., Muhlich, J., Serrano, M., Ferraiolo, P., Tolliday, N. J., Schreiber, S. L., and Clemons, P. A. (2008) Chem-Bank: a small molecule screening and cheminformatics resource database. Nucleic Acids Res. 36, 351-359
21. LeVine, H., 3rd (1993) Thioflavin T interaction with synthetic Alzheimer disease β-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 2, 404-410
22. Johansson, A. S., Berglind-Dehlin, F., Karlsson, G., Edwards, K., Gellerfors, P., and Lannfelt, L. (2006) Physiochemical characterization of the Alzheimer disease-related peptides Aβ1-42Arctic and A β1-42wt. FEBS J. 273, 2618-2630
23. Lee, S., Fernandez, E. J., and Good, T. A. (2007) Role of aggregation conditions in structure, stability, and toxicity of intermediates in the Aβ fibril formation pathway. Protein Sci. 16, 723-732 (Pubitemid 46507001)
24. Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., Wals, P., Zhang, C., Finch, C. E., Krafft, G. A., and Klein, W. L. (1998) Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U.S.A. 95, 6448-6453
25. Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., and Ashe, K. H. (2005) Natural oligomers of the amyloid β protein specifically disrupt cognitive function. Nat. Neurosci. 1, 79-84 (Pubitemid 41236735)
26. Barghorn, S., Nimmrich, V., Striebinger, A., Krantz, C., Keller, P., Janson, B., Bahr, M., Schmidt, M., Bitner, R. S., Harlan, J., Barlow, E., Ebert, U., and Hillen, H. (2005) Globular amyloid β peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer disease. J. Neurochem. 95, 834-847 (Pubitemid 41567174)
27. Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-63
28. Mazza, M., Capuano, A., Bria, P., and Mazza, S. (2006) Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer dementia in a randomized placebo-controlled double-blind study. Eur. J. Neurol. 13, 981-985 (Pubitemid 44284905)
29. Yao, Z., Drieu, K., and Papadopoulos, V. (2001) The Ginkgo biloba extract EGb761 rescues the PC12 neuronal cells from β-amyloid-induced cell death by inhibiting the formation of β-amyloid-derived diffusible neurotoxic ligands. Brain Res. 889, 181-190 (Pubitemid 32146280)
30. 2-induced neuroblastoma cell cytotoxicity by a triazine derivative, AA3E2. Eur. J. Pharmacol. 622, 1-6
31. Yazdanparast, R., and Shaykhalishahi, H. (2009) Protective effect of a tri-azine- derivative (AA3E2) on β-amyloid-induced damages in SK-N-MC cells. Toxicol. in Vitro 23, 1277-1283
32. Crowther, D. C., Kinghorn, K. J., Miranda, E., Page, R., Curry, J. A., Duthie, F. A., Gubb, D. C., and Lomas, D. A. (2005) Intraneuronal Aβ, nonamyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer disease. Neuroscience 132, 123-135 (Pubitemid 40380720)
33. Pandey, U. B., and Nichols, C. D. (2011) Human disease models in Drosophila melanogaster and the role of the fly in therapeutic drug discovery. Pharmacol. Rev. 63, 411-436
34. Iijima, K., Chiang, H. C., Hearn, S. A., Hakker, I., Gatt, A., Shenton, C., Granger, L., Leung, A., Iijima-Ando, K., and Zhong, Y. (2008) Aβ42 mutants with different aggregation profiles induce distinct pathologies in Drosophila. PLoS ONE 3, e1703
35. Luheshi, L. M., Tartaglia, G. G., Brorsson, A. C., Pawar, A. P., Watson, I. E., Chiti, F., Vendruscolo, M., Lomas, D. A., Dobson, C. M., and Crowther, D. C. (2007) Systematic in vivo analysis of the intrinsic determinants of amyloid β pathogenicity. PLoS Biol. 5, e290
36. Crowther, D. C., Page, R., Chandraratna, D., and Lomas, D.A. (2006) A Drosophila model of Alzheimer disease. Methods Enzymol. 412, 234-255
37. Scherzer-Attali, R., Pellarin, R., Convertino, M., Frydman-Marom, A., Egoz-Matia, N., Peled, S., Levy-Sakin, M., Shalev, D. E., Caflisch, A., Gazit, E., and Segal, D. (2010) Complete phenotypic recovery of an Alzheimer disease model by a quinone-tryptophan hybrid aggregation inhibitor. PLoS ONE 5, e11101
38. Frydman-Marom, A., Levin, A., Farfara, D., Benromano, T., Scherzer- Attali, R., Peled, S., Vassar, R., Segal, D., Gazit, E., Frenkel, D., and Ovadia, M. (2011) Orally administrated cinnamon extract reduces β-amyloid oligomerization and corrects cognitive impairment in Alzheimer disease animal models. PLoS ONE 6, e16564